Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company focused on therapies for liver and viral diseases, and its news flow reflects progress across this pipeline. Company announcements frequently highlight developments in chronic hepatitis B virus (HBV) programs, obesity and metabolic dysfunction-associated steatohepatitis (MASH) research, and broader corporate activities.
News items include updates on pevifoscorvir sodium, an oral capsid assembly modulator (CAM-E) under investigation for chronic HBV infection. Aligos issues press releases on clinical trial milestones, such as the initiation and enrollment of the Phase 2 B-SUPREME study, as well as data presentations at major scientific meetings. These communications describe antiviral activity, biomarker changes, and study designs that are central to understanding the company’s HBV strategy.
Investors and observers can also find coverage of ALG-055009, a THR-β agonist being studied for obesity and MASH. News from Aligos has detailed nonclinical in vivo results in diet-induced obese mouse models, showing synergistic body weight and fat mass loss when ALG-055009 is combined with incretin receptor agonists such as semaglutide or tirzepatide. Such updates provide insight into how the company positions this candidate within emerging combination approaches in cardiometabolic disease.
Beyond pipeline data, the ALGS news stream includes corporate and financial disclosures such as quarterly business updates, financial results, inducement grants under Nasdaq Listing Rule 5635(c)(4), amendments to equity plans, and senior leadership appointments. The company also announces participation in healthcare and investor conferences, where members of management discuss strategy and development programs.
By following ALGS news, readers can track clinical progress, preclinical findings, capital and governance actions, and organizational developments that shape Aligos Therapeutics’ efforts in liver and viral disease therapeutics.
Aligos Therapeutics (Nasdaq: ALGS) will present four posters at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL) from February 4-6, 2021. The presentations will showcase progress in their chronic hepatitis B (CHB) drug candidates, ALG-010133 and ALG-000184, currently in Phase 1a/b studies. Notable findings include ALG-010133's promising preclinical efficacy and pharmacokinetics, and ALG-000184's safety and tolerability data. These trials aim to develop effective combination therapies against CHB.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced that CEO Lawrence Blatt will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 3:40 PM ET. The presentation will include a virtual Q&A session, with the webcast recording available for 30 days afterward. Aligos focuses on developing novel therapeutics for viral infections and liver diseases, particularly targeting chronic hepatitis B and nonalcoholic steatohepatitis. Founded in 2018, the company aims to lead in antiviral therapies using its extensive drug development expertise.
Aligos Therapeutics (Nasdaq: ALGS) recently presented at the RespiDART & Emerging Viruses 2020 meeting, showcasing advancements in their SARS-CoV-2 therapeutic candidate, ALG-097111. The presentation underscored the development of a multiplex screening platform to identify selective inhibitors for the viral 3CLpro protease, essential for viral replication. ALG-097111 demonstrated significant inhibition without affecting human cathepsin L, highlighting its potential as a targeted treatment for SARS-CoV-2. Collaborations with KU Leuven were pivotal in these developments.
Aligos Therapeutics (Nasdaq: ALGS) announced a collaboration with Merck to leverage its oligonucleotide platform technology for developing therapies targeting non-alcoholic steatohepatitis (NASH) and potentially other conditions. The agreement includes an upfront payment and up to $458M in development milestones along with tiered royalties on sales. Aligos will focus on designing and optimizing oligonucleotides, while Merck will handle clinical development and commercialization. This collaboration aims to address the critical need for effective NASH treatments amidst growing liver disease concerns.
Aligos Therapeutics (Nasdaq: ALGS) presented six posters and one oral presentation at the AASLD Liver Meeting Digital Experience 2020, highlighting advancements in its liver disease programs. Key updates included progress on chronic hepatitis B (CHB) therapies and the nonalcoholic steatohepatitis (NASH) treatment candidate ALG-055009. The company is optimistic about its combination regimens for CHB that may lead to functional cures and has begun Phase 1 trials for two drug candidates, ALG-010133 and ALG-000184, aimed at CHB.
Aligos Therapeutics (Nasdaq: ALGS) announced participation in two virtual investor conferences: the Jefferies 2020 Virtual London Healthcare Conference from November 17-19, and the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3. Management will present at both events and will be available for one-on-one meetings. Aligos focuses on developing novel therapeutics for viral infections and liver diseases, aiming to advance targeted antiviral therapies.
Aligos Therapeutics (Nasdaq: ALGS) has announced that its Belgian subsidiary, Aligos Belgium BV, received a €1.8M grant from the Flemish Agency for Innovation and Entrepreneurship (VLAIO) to support a nonclinical research project on combination therapy for Chronic Hepatitis B (CHB). This three-year project, named CoHeBA, aims to explore the therapeutic candidates' mechanisms and involves collaborations with leading laboratories globally. Aligos CEO Lawrence Blatt expressed optimism that project outcomes will enhance their therapeutic developments for CHB, which affects over 290 million people worldwide.
Aligos Therapeutics (Nasdaq: ALGS) announced the dosing of its first subject in the Phase 1a/b trial of ALG-000184, a novel treatment targeting hepatitis B virus (HBV). This trial aims to assess the safety, pharmacokinetics, and antiviral activity of ALG-000184 in patients with chronic hepatitis B. The company anticipates sharing initial topline results in the second half of 2021. The trial marks the second drug candidate from Aligos’s CHB portfolio to enter clinical studies this year, affirming their commitment to developing innovative therapies for unmet medical needs in liver diseases.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) has priced its initial public offering of 10 million shares at $15.00 each, aiming for gross proceeds of approximately $150 million. The underwriters have a 30-day option for an additional 1.5 million shares. The common stock will commence trading on Nasdaq on October 16, 2020, with the offering expected to close on October 20, 2020, pending customary conditions. J.P. Morgan, Jefferies, and Piper Sandler are managing the offering.